← Back to all trials
Recruiting
NCT07704047
A Clinical Study of FT1 in Patients With Short Bowel Syndrome
Conditions: Short Bowel Syndrome, SBS
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 8
Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
Location: General Hospital of Eastern Theater Command Nanjing Jiangsu
Summary
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.
Participants will
* Receive multiple injections of FT1 or placebo according to weight.
* Visit the clinic for assessment.
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years, male or female.
* SBS secondary to surgical resection of the small intestine, screened for at least 12 months after pre intestinal resection surgery;
* Stable weight before screening; For patients requiring parenteral support (PS), PS volume remained stable (with changes in volume or energy content\
Source: ClinicalTrials.gov (NCT07704047). StuddyBuddy aggregates publicly available trial information.
